Infantile Spasm Therapeutics Market Size Worth $181.85 Million By 2032 |CAGR: 3.2%

Infantile Spasm Therapeutics Market Size Worth $181.85 Million By 2032 |CAGR: 3.2%

The infantile spasm therapeutics market size is expected to reach USD 181.85 million by 2032, according to a new study by Polaris Market Research. The report Infantile Spasm Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class (Anticonvulsants, Corticosteroids, Others); By Drug Type; By Dosage, By Route of Administration; By Distribution Channel; and Region 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market has witnessed some revolutionary drug developments including generic drugs, for e.g., MSN Labs launched India’s first generic Vigabatrin (Viganext) that is to be administered as a powder. The recent technological advancements particularly in advance treatment and preventive treatment of Infantile Spasm Therapeutics, like development of non-invasive automated seizure detection device that help in early detection of seizure to provide better solutions for to treat the disorder. Due to presence of telemedicine and teleconsultation, during the times of COVID-19, Infantile Spasm Therapeutics market has seen a jump as it was widely used during the times of lockdown. This huge demand was seen due to the advantages of easy and comfortable check-up, consultation from across the globe amongst others.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

The presence and increase of awareness campaigns like that of Infantile Spasm Therapeutics Awareness Week every first week of December across the globe contribute to positively impacting the market. Also, the growing demand for novel and compliant drugs is made possible by an increasing concentration on investments associated to research and development, which leads to an increase in new drug development. According to World Bank data, 2.63% of global GDP is invested in research and development of better alternatives to the drugs available in the market.

Infantile Spasm Therapeutics Market Report Highlights

  • The anticonvulsants segment accounted for the largest revenue share. This is due to its higher efficacy and ease of tolerance in patients undergoing treatment
  • Adrenocorticotropic hormone segment accounted to hold largest revenue share as it is preferred by the clinicians and prescribers to treat Infantile Spasm Therapeutics owing to its safety and efficacy making it the drug of choice
  • Liquid segment accounted for largest market share due to its advantages like ease of administration in infantile patients, high patient compliance, and rapid onset of action
  • Hospital Pharmacy segment account for a largest market share owing to the reason that Infantile Spasm Therapeutics requires treatment in presence of a medical practitioner and, hospital pharmacies provide convenience as compared to other modes of distribution
  • North America dominated the market as there is more early acceptance of techniques, better and more developed healthcare infrastructure and constant drive for product innovation.
  • The major players in the market include Lundbeck, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals, Retrophin, Valerion Therapeutics, Orphelia Pharma, Insys Therapeutics, & Anavex Life Sciences.

Polaris Market Research has segmented the Infantile Spasm Therapeutics market report based on therapeutic class, dosage, route of administration, distribution channel, drug type, and region:        

Infantile Spasm Therapeutics Market, Therapeutic Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasm Therapeutics Market, Drug Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Infantile Spasm Therapeutics Market, Dosage Outlook (Revenue - USD Million, 2019 - 2032)

  • Solid
  • Liquid

Infantile Spasm Therapeutics Market, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parenteral
  • Others

Infantile Spasm Therapeutics Market, Distribution Channel Outlook (Revenue - USD Million, 2019 -2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Infantile Spasm Therapeutics Market, Region Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Infantile Spasm Therapeutics Market Report Scope

Report Attributes


Market size value in 2024

USD 141.07 million

Revenue forecast in 2032

USD 181.85 million


3.2% from 2024 - 2032

Base year


Historical data

2019 - 2022

Forecast period

2024 - 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

By Therapeutic Class, By Drug Type, By Dosage, By Route of Administration, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.

For Specific Research Requirements

Request for Customized Report